MCID: MYC006
MIFTS: 73

Mycosis Fungoides

Categories: Rare diseases, Cancer diseases, Immune diseases, Skin diseases, Blood diseases

Aliases & Classifications for Mycosis Fungoides

MalaCards integrated aliases for Mycosis Fungoides:

Name: Mycosis Fungoides 53 37 12 72 49 24 36 51 41 14 69
Mycosis Fungoides Lymphoma 12 72
Alibert-Bazin Syndrome 49 24
Granuloma Fungoides 49 24
Mycosis Fungoides, Unspecified Site, Extranodal and Solid Organ Sites 12
Mycosis Fungoides of Unspecified Site 12
Mycosis Fungoides, Alibert-Bazin Type 55
Classic Mycosis Fungoides 55
Mycosis Fungoides Nos 12
Mf 12

Characteristics:

Orphanet epidemiological data:

55
classic mycosis fungoides
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

OMIM:

53
Inheritance:
familial aggregation without simple mendelian pattern


Classifications:



Summaries for Mycosis Fungoides

OMIM : 53 Mycosis fungoides is a malignant T-cell lymphoma of the skin, first reported (and named) by Alibert (1835). Sezary syndrome is a leukemic variant of mycosis fungoides defined by erythroderma with greater than 80% of the skin showing redness, adenopathy and greater than 1,000 circulating Sezary cells/microliter with a CD4+CD26- or CD4+CD7- phenotype. Sezary cells have a type 2 helper T cell cytokine profile. Sezary syndrome has a median overall survival time of only 2.4 years in patients with Sezary cells at a density of greater than 10,000 cells/microliter or 5.4 years in patients with 1,000-10,000 Sezary cells/microliter. Mycosis fungoides and Sezary syndrome are the most common cutaneous T-cell lymphomas. Sezary syndrome can arise de novo or can appear following years of chronic mycosis fungoides. Both are thought to arise from clonal expansion of CD4+ helper T cells responding to chronic antigen stimulation (summary by Wang et al., 2015). (254400)

MalaCards based summary : Mycosis Fungoides, also known as mycosis fungoides lymphoma, is related to cutaneous t cell lymphoma and follicular mucinosis, and has symptoms including pruritus, edema and dry skin. An important gene associated with Mycosis Fungoides is TNFRSF1B (TNF Receptor Superfamily Member 1B), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Abraxane and Methoxsalen have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone, and related phenotypes are hematopoietic system and immune system

NIH Rare Diseases : 49 Mycosis fungoides is a disease in which T-celllymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin. This condition is one of the most common types of T-cell lymphoma. Mycosis fungoides is characterized by a scaly, red rash that develops on the skin, particularly on areas that are not usually exposed to the sun. The rash may last for months or years without causing any symptoms. Over time, a thin, reddened, eczema-like rash may develop, followed by thickened, red patches of skin. Finally, tumors form which may develop into ulcers and become infected. Mycosis fungoides is difficult to cure. Treatment is usually palliative, with the intention of relieving symptoms and improving the quality of life. Last updated: 1/26/2011

Genetics Home Reference : 24 Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. Although the skin is involved, the skin cells themselves are not cancerous. Mycosis fungoides usually occurs in adults over age 50, although affected children have been identified.

Wikipedia : 72 Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form... more...

Related Diseases for Mycosis Fungoides

Diseases related to Mycosis Fungoides via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 233)
# Related Disease Score Top Affiliating Genes
1 cutaneous t cell lymphoma 32.4 CCL17 IFNA1 IL2 IL2RA TIA1 TNFRSF8
2 follicular mucinosis 31.5 CD7 IFNA2 TNFRSF8
3 pityriasis lichenoides 31.3 CD7 TNFRSF8
4 dermatitis 31.1 CCL17 CCL22 IL5 STAT3
5 sezary's disease 31.1 CD28 CD7 CTLA4 DPP4 IFNA1 IL2
6 adult t-cell leukemia 30.9 CD7 IL2 IL2RA TNFRSF8
7 dermatitis, atopic 30.5 CCL17 CCL22 CXCR3 IL2 IL2RA IL5
8 psoriasis 30.4 CCL17 CCL22 CXCL9 CXCR3 IL2 IL2RA
9 lymphoma, hodgkin, classic 30.4 CCL17 IL2 IL2RA TIA1 TNFRSF8
10 alopecia areata 30.4 CTLA4 CXCL9 IL2 IL2RA
11 hypereosinophilic syndrome 30.4 CCL17 IFNA1 IL2RA IL5
12 cryoglobulinemia, familial mixed 30.3 IFNA1 IFNA2
13 lymphoma, non-hodgkin, familial 30.3 CDKN2B IL2 IL2RA TNFRSF8
14 leukemia, acute myeloid 30.3 CD7 CDKN2B IL2 STAT3
15 leukemia, chronic lymphocytic 30.2 CXCR3 IL2 IL2RA STAT3 TNFRSF8
16 b-cell expansion with nfkb and t-cell anergy 30.2 CD28 IL2 IL2RA TIA1
17 uveitis 30.2 CTLA4 CXCR3 IFNA2 IL2RA
18 hairy cell leukemia 29.9 IFNA1 IFNA2 IL2 IL2RA ITGAE
19 systemic lupus erythematosus 29.3 CD28 CTLA4 CXCR3 IFNA1 IL2 IL2RA
20 folliculotropic mycosis fungoides 12.6
21 marfan syndrome 11.6
22 shprintzen-goldberg craniosynostosis syndrome 11.1
23 monofixation syndrome 11.1
24 neonatal marfan syndrome 10.9
25 homocystinuria due to cystathionine beta-synthase deficiency 10.9
26 microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma 10.9
27 lymphoma 10.9
28 granulomatous slack skin disease 10.7
29 localized pagetoid reticulosis 10.7
30 pityriasis lichenoides et varioliformis acuta 10.6 CD7 TNFRSF8
31 paragonimiasis 10.6 CCL17 CXCR3 IL5
32 erythema multiforme 10.6 CCL17 CXCR3 IL2
33 parapsoriasis 10.6
34 atopic keratoconjunctivitis 10.6 CCL22 IL2 IL5
35 necatoriasis 10.6 CCL17 CCL22 IL5
36 apple allergy 10.6 CCL17 CCL22 IL5
37 intermediate uveitis 10.6 CXCR3 IL2 IL2RA
38 squamous papillomatosis 10.6 IFNA1 IFNA2
39 radiculopathy 10.5 CXCR3 IL2RA IL5
40 keratoconjunctivitis 10.5 CCL17 IL2 IL5
41 pustulosis palmaris et plantaris 10.5 CXCR3 IL5 ITGB2
42 wells syndrome 10.5 IL2 IL2RA IL5
43 allergic contact dermatitis 10.5 CCL17 CXCR3 IL5
44 leukocyte disease 10.5 IFNA1 IL2 IL5
45 eosinophilic pneumonia 10.5 CCL17 CCL22 IL5
46 lymphomatoid papulosis 10.5
47 tropical spastic paraparesis 10.5 CXCR3 IL2 IL2RA
48 pulmonary sarcoidosis 10.5 CXCR3 IL2 IL2RA
49 contact dermatitis 10.5 CCL17 CCL22 CXCR3 IL5
50 pure red-cell aplasia 10.5 IL2 IL2RA STAT3

Graphical network of the top 20 diseases related to Mycosis Fungoides:



Diseases related to Mycosis Fungoides

Symptoms & Phenotypes for Mycosis Fungoides

Symptoms via clinical synopsis from OMIM:

53
Skin:
pruritus
erythema
malignant t-cell skin lymphoma
skin scaling
psoriasiform dermatitis
more
Lymphatics:
lymphadenopathy


Clinical features from OMIM:

254400

Human phenotypes related to Mycosis Fungoides:

55 31 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pruritus 55 31 hallmark (90%) Very frequent (99-80%) HP:0000989
2 edema 55 31 occasional (7.5%) Occasional (29-5%) HP:0000969
3 dry skin 55 31 hallmark (90%) Very frequent (99-80%) HP:0000958
4 splenomegaly 55 31 occasional (7.5%) Occasional (29-5%) HP:0001744
5 hepatomegaly 55 31 occasional (7.5%) Occasional (29-5%) HP:0002240
6 abnormality of the nail 55 31 occasional (7.5%) Occasional (29-5%) HP:0001597
7 hyperkeratosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000962
8 alopecia 55 31 frequent (33%) Frequent (79-30%) HP:0001596
9 skin ulcer 55 31 occasional (7.5%) Occasional (29-5%) HP:0200042
10 hypopigmented skin patches 55 31 frequent (33%) Frequent (79-30%) HP:0001053
11 irregular hyperpigmentation 55 31 frequent (33%) Frequent (79-30%) HP:0007400
12 neoplasm of the skin 55 31 hallmark (90%) Very frequent (99-80%) HP:0008069
13 erythema 55 31 hallmark (90%) Very frequent (99-80%) HP:0010783
14 skin rash 55 31 hallmark (90%) Very frequent (99-80%) HP:0000988
15 eczema 55 31 hallmark (90%) Very frequent (99-80%) HP:0000964
16 lymphoma 55 31 Very frequent (99-80%) HP:0002665
17 lymphadenopathy 55 31 frequent (33%) Frequent (79-30%) HP:0002716
18 abnormality of bone marrow cell morphology 55 31 occasional (7.5%) Occasional (29-5%) HP:0005561
19 skin plaque 55 31 hallmark (90%) Very frequent (99-80%) HP:0200035
20 poikiloderma 55 31 frequent (33%) Frequent (79-30%) HP:0001029
21 cutaneous t-cell lymphoma 55 31 frequent (33%) Frequent (79-30%) HP:0012192
22 abnormality of the eyelid 55 Occasional (29-5%)
23 abnormality of lymphocytes 55 Very frequent (99-80%)
24 psoriasiform dermatitis 31 HP:0003765
25 abnormal eyelid morphology 31 occasional (7.5%) HP:0000492
26 abnormal lymphocyte morphology 31 hallmark (90%) HP:0004332

MGI Mouse Phenotypes related to Mycosis Fungoides:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 TNFRSF1B IL2 CCL17 IL2RA CD28 IL5
2 immune system MP:0005387 10.06 TNFRSF1B IL2 CCL17 CCL22 IL2RA CD28
3 endocrine/exocrine gland MP:0005379 10.02 TNFRSF1B IL2 IL2RA CD28 CD7 CDKN2B
4 digestive/alimentary MP:0005381 9.91 IL2 IL2RA CD28 IL5 CTLA4 STAT3
5 neoplasm MP:0002006 9.5 IL2 CD28 IL5 CDKN2B STAT3 CXCR3
6 respiratory system MP:0005388 9.17 IL2 IL2RA IL5 CTLA4 STAT3 CXCR3

Drugs & Therapeutics for Mycosis Fungoides

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 45 PACLITAXEL Celgene October 2012

Drugs for Mycosis Fungoides (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 361)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1 298-81-7 4114
2
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 153559-49-0 82146
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
4
Denileukin diftitox Approved, Investigational Phase 4,Phase 2 173146-27-5
5
Vorinostat Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 149647-78-9 5311
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
7
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
8 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
13 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
14 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2
21 Interferon-alpha Phase 4,Phase 2
22 interferons Phase 4,Phase 2,Phase 1,Early Phase 1
23 Histone Deacetylase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
24 Clorazepate Dipotassium Phase 4
25 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
28
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
29
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
30
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
31
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
32
Ofloxacin Approved Phase 3 82419-36-1 4583
33
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
34
Etoposide Approved Phase 2, Phase 3, Phase 1, Early Phase 1 33419-42-0 36462
35
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
36
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 460612 4053
37 Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
38
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1 23214-92-8 31703
39
Panobinostat Approved, Investigational Phase 2, Phase 3, Phase 1 404950-80-7 6918837
40
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 209810-58-2, 11096-26-7
41
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
43
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
44
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
45
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
46
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2 93-14-1 3516
47
Morphine Approved, Investigational Phase 3 57-27-2 5288826
48
Ondansetron Approved Phase 3,Phase 2 99614-02-5 4595
49
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
50
Captopril Approved Phase 3 62571-86-2 44093

Interventional clinical trials:

(show top 50) (show all 384)

# Name Status NCT ID Phase Drugs
1 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
2 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
3 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
4 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
5 Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Recruiting NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
6 PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
7 Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study Withdrawn NCT01801670 Phase 4
8 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
9 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
10 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
11 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3 Panobinostat
12 Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Completed NCT00490776 Phase 2, Phase 3 LBH589
13 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
14 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
15 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
16 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
17 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
18 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
19 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
20 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
21 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
22 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
23 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
24 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
25 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
26 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
27 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
28 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
29 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Recruiting NCT02448381 Phase 3 SGX301 (synthetic hypericin);Placebo
30 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Recruiting NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
31 PUVA Maintenance Therapy in Mycosis Fungoides Active, not recruiting NCT01686594 Phase 3 8-methoxypsoralen
32 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Active, not recruiting NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate or Bexarotene
33 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
34 Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
35 Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides Terminated NCT00056056 Phase 3 bexarotene;methoxypsoralen
36 Lenalidomide Maintenance Post-debulking in Advanced CTCL Terminated NCT01098656 Phase 3 lenalidomide
37 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
38 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
39 Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
40 Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2 alemtuzumab
41 Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides Unknown status NCT00002557 Phase 2 CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate
42 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
43 Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma Unknown status NCT00030589 Phase 2 bexarotene;methoxsalen
44 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
45 Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma Unknown status NCT00474929 Phase 1, Phase 2 RAD001;Sorafenib
46 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
47 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
48 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
49 Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides Completed NCT00168064 Phase 2 mechlorethamine-MCH (nitrogen mustard)
50 An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides Completed NCT00535470 Phase 2 0.04% Mechlorethamine gel

Search NIH Clinical Center for Mycosis Fungoides

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mycosis Fungoides cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: mycosis fungoides

Genetic Tests for Mycosis Fungoides

Anatomical Context for Mycosis Fungoides

MalaCards organs/tissues related to Mycosis Fungoides:

38
T Cells, Skin, Bone, Bone Marrow, B Cells, Liver, Lung

Publications for Mycosis Fungoides

Articles related to Mycosis Fungoides:

(show top 50) (show all 992)
# Title Authors Year
1
Verrucous mycosis fungoides. ( 29417797 )
2018
2
Folliculotropic mycosis fungoides presenting with a solitary lesion: Clinicopathological features and long-term follow-up data in a series of 9 cases. ( 29086994 )
2018
3
Clinical and histological evaluation in patients with mycosis fungoides treated with UVA1. ( 29368862 )
2018
4
Increased interleukin-36I^ expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/SAczary syndrome. ( 29314201 )
2018
5
Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B cell Lymphoma and Acute Myeloid Leukemia: A Report of Two Cases. ( 29321428 )
2018
6
Successful treatment of extensive splanchnic vein thrombosis in a patient with mycosis fungoides. ( 29437735 )
2018
7
Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data. ( 29440874 )
2018
8
Current systemic therapeutic options for advanced mycosis fungoides and SAczary syndrome. ( 29308723 )
2018
9
Intraocular involvement of mycosis fungoides associated with immunophenotypic switch from CD4+ to CD8. ( 29298755 )
2018
10
Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms. ( 29341283 )
2018
11
How to Discern Folliculotropic Mycosis Fungoides From Follicular Mucinosis Using a Pediatric Case. ( 29318909 )
2018
12
A high expression of cell adhesion molecule 1 (CADM1) is an unfavorable prognostic factor in mycosis fungoides. ( 29391198 )
2018
13
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome. ( 29196934 )
2018
14
Mycosis fungoides in patients with psoriasis: an ongoing issue. ( 29336316 )
2018
15
Hypopigmented mycosis fungoides: a 20-case retrospective series. ( 29318586 )
2018
16
Hypopigmented Mycosis Fungoides Treated with 308 nm Excimer Laser. ( 29386841 )
2018
17
Etoposide as a single agent in the treatment of mycosis fungoides: A retrospective analysis. ( 29316111 )
2018
18
Type D (CD8+) lymphomatoid papulosis in a patient with classic (CD4+) mycosis fungoides. ( 29378678 )
2018
19
Case report: photo-onycholysis after PUVA treatment for hypopigmented mycosis fungoides with response to topical steroid. ( 29445460 )
2018
20
Photodynamic therapy: an option in mycosis fungoides. ( 28890210 )
2017
21
Phototherapy of mycosis fungoides. ( 28845954 )
2017
22
A possible association between mycosis fungoides and Muir-Torre syndrome: Two disorders with microsatellite instability. ( 28761921 )
2017
23
Relationship Between Pityriasis Lichenoides and Mycosis Fungoides: A Clinicopathological, Immunohistochemical, and Molecular Study. ( 29210716 )
2017
24
Maintenance therapy with psoralen-ultraviolet A for mycosis fungoides: in the absence of evidence sitting on the fence is appropriate. ( 28833022 )
2017
25
Mycosis fungoides with CD30-positive large-cell transformation clinically mimicking scarring alopecia. ( 28834192 )
2017
26
The role of macrophages in the pathogenesis of mycosis fungoides. ( 28436576 )
2017
27
Frequency and Risk Factors for Secondary Malignancies in Patients With Mycosis Fungoides. ( 28832009 )
2017
28
Folliculotropic Mycosis Fungoides Associated with Autoimmune Hepatitis. ( 29252180 )
2017
29
Mycosis fungoides occurring at the site of previous herpes zoster eruption. ( 29280139 )
2017
30
Feasibility study in teledermatopathology: An examination of the histopathologic features of mycosis fungoides and spongiotic dermatitis. ( 28796294 )
2017
31
Mycosis Fungoides in Pediatric Patients: A Diagnostic Challenge. ( 28473054 )
2017
32
Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and SAczary syndrome. ( 28925057 )
2017
33
Periorbital Involvement in Early Stage Mycosis Fungoides. ( 28421231 )
2017
34
High Expression of Fas/CD95 on CD4+ Circulating T Cells: An Exclusion Criterion in the Diagnosis of Mycosis Fungoides? ( 28206666 )
2017
35
Lymphoproliferative CD30-positive disorder in a patient with a folliculotropic mycosis fungoides. ( 28387989 )
2017
36
Remarkable Advances in the Management of Mycosis Fungoides and the Sezary Syndrome. ( 28423383 )
2017
37
Computed Tomography scanning in mycosis fungoides - optimising the balance between benefit and harm. ( 28498608 )
2017
38
Hypopigmented Mycosis Fungoides: Clinical, Histological, and Immunohistochemical Remission Induced by Narrow-band Ultraviolet B. ( 28400643 )
2017
39
Immunohistopathological Study of c-FLIP Protein in Mycosis Fungoides ( 28952283 )
2017
40
Toll-like receptor (TLR)7 expression in mycosis fungoides and psoriasis: a case-control study. ( 28054376 )
2017
41
Successful treatment of relapsed folliculotropic mycosis fungoides with mogamulizumab followed by intensity-modulated radiotherapy. ( 29068082 )
2017
42
Folliculotropic mycosis fungoides: challenging clinical, histopathological and immunohistochemical diagnosis. ( 29267452 )
2017
43
Interstitial Mycosis Fungoides: Setting the Record Straight. ( 27984240 )
2017
44
Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group. ( 28132406 )
2017
45
CD4-Positive T-Cell Large Granular Lymphocytosis Mimicking Sezary Syndrome in a Patient With Mycosis Fungoides. ( 28441377 )
2017
46
Pediatric mycosis fungoides: a study of the human leukocyte antigen system among Israeli Jewish patients. ( 28948342 )
2017
47
CD30-positive lymphoproliferative Erkrankung bei einem Patienten mit follikulotroper Mycosis fungoides. ( 28485861 )
2017
48
Folliculotropic mycosis fungoides associated with atopic dermatitis. ( 28731507 )
2017
49
Fulminant Mycosis Fungoides with Tissue Eosinophilia: A Unique Presentation of Two Cases with Acro-Periorbital Ulceration and An Aggressive Clinical Course. ( 28758048 )
2017
50
Oral and Cutaneous Lymphomas other than Mycosis Fungoides and SAczary Syndrome in a Mexican Cohort: Recategorization and Evaluation of International Geographical Disparities. ( 28400635 )
2017

Variations for Mycosis Fungoides

Cosmic variations for Mycosis Fungoides:

9 (show top 50) (show all 88)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM5574238 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.752A>G p.Y251C 22
2 COSM5574244 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2668A>C p.T890P 22
3 COSM5574236 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.517C>T p.P173S 22
4 COSM11073 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1024C>T p.R342* 22
5 COSM11166 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.406C>T p.Q136* 22
6 COSM44854 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.655C>A p.P219T 22
7 COSM44036 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.296C>T p.S99F 22
8 COSM44312 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.511G>A p.E171K 22
9 COSM45449 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.592G>C p.E198Q 22
10 COSM45796 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.623A>G p.D208G 22
11 COSM10768 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.535C>T p.H179Y 22
12 COSM110772 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4474G>T p.E1492* 22
13 COSM5574229 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1918C>T p.Q640* 22
14 COSM42016 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4393C>T p.R1465* 22
15 COSM5574231 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.521C>A p.P174H 22
16 COSM100075 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4193T>C p.L1398P 22
17 COSM1716590 STAT5B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1924A>C p.N642H 22
18 COSM1717514 STAT3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1492A>G p.I498V 22
19 COSM1155743 STAT3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1919A>T p.Y640F 22
20 COSM5574219 SETD1A haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1211G>A p.R404H 22
21 COSM3734685 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1034C>T p.S345F 22
22 COSM5574251 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3473G>A p.R1158H 22
23 COSM3734686 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1559C>T p.S520F 22
24 COSM5049787 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1025A>G p.D342G 22
25 COSM5049788 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1024G>A p.D342N 22
26 COSM3405078 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3487G>A p.E1163K 22
27 COSM580 NRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.181C>A p.Q61K 22
28 COSM4591233 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.534G>C p.K178N 22
29 COSM126825 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2125C>T p.Q709* 22
30 COSM5574213 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3360G>C p.E1120D 22
31 COSM5574204 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.6038C>T p.P2013L 22
32 COSM5574211 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.6322C>T p.Q2108* 22
33 COSM5574208 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.76C>A p.Q26K 22
34 COSM5574196 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.11845C>T p.Q3949* 22
35 COSM5574193 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4475G>C p.S1492T 22
36 COSM30358 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.7495G>A p.D2499N 22
37 COSM5574203 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.5923C>G p.L1975V 22
38 COSM34214 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1715C>T p.A572V 22
39 COSM51374 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1533G>A p.M511I 22
40 COSM5574250 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3067T>C p.Y1023H 22
41 COSM5574248 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2128C>G p.L710V 22
42 COSM2239136 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1961A>T p.Y654F 22
43 COSM3734693 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1975C>T p.R659C 22
44 COSM1025793 DNMT3B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.895C>T p.R299* 22
45 COSM5574188 DNMT3B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2292G>T p.R764S 22
46 COSM5574184 DNMT3A haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2120G>A p.G707D 22
47 COSM5574186 DNMT3A haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1752C>A p.Y584* 22
48 COSM220934 CARD11 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1201G>A p.D401N 22
49 COSM403987 BCOR haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4274A>G p.N1425S 22
50 COSM5574182 ARID5B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2242C>T p.R748W 22

Expression for Mycosis Fungoides

Search GEO for disease gene expression data for Mycosis Fungoides.

Pathways for Mycosis Fungoides

Pathways related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 CCL22 CD28 CTLA4 IFNA1 IFNA2 IL2
2
Show member pathways
13.75 CCL17 CCL22 CD28 CDKN2B CXCL9 CXCR3
3
Show member pathways
13.61 CCL17 CCL22 CD28 CXCL9 CXCR3 IFNA1
4
Show member pathways
13.51 CCL17 CCL22 IFNA1 IFNA2 IL2 IL2RA
5
Show member pathways
13.33 CCL22 IFNA1 IFNA2 IL2 IL2RA IL5
6
Show member pathways
13.26 CCL17 CCL22 CD28 CXCL9 CXCR3 IL2
7
Show member pathways
13.11 CCL17 CCL22 CD28 CXCL9 CXCR3 IL2
8
Show member pathways
12.83 CCL17 CCL22 CXCL9 CXCR3 STAT3
9 12.83 CDKN2B IFNA1 IFNA2 IL2 IL2RA IL5
10
Show member pathways
12.8 CD28 CTLA4 CXCL9 IFNA1 IFNA2 IL2
11
Show member pathways
12.77 CD28 IFNA1 IFNA2 IL2 IL2RA STAT3
12
Show member pathways
12.58 CD28 IL2 IL2RA IL5 STAT3
13
Show member pathways
12.39 CD28 CTLA4 IL2 IL5
14 12.38 CDKN2B IL2 IL2RA ITGB2
15
Show member pathways
12.35 CD28 CTLA4 IL2 IL2RA
16
Show member pathways
12.33 IFNA1 IFNA2 IL2 IL2RA IL5 STAT3
17
Show member pathways
12.18 CCL17 CCL22 CXCL9 CXCR3 ITGAE ITGB2
18
Show member pathways
12.15 IFNA1 IFNA2 IL2 IL5
19 12.12 CD28 CTLA4 IFNA1 IL2 IL2RA ITGB2
20
Show member pathways
12.03 IL2 IL2RA IL5 STAT3
21 12.01 CD28 IFNA2 IL2 IL2RA IL5
22
Show member pathways
11.99 CCL17 CCL22 CXCL9 CXCR3
23 11.97 CCL22 ITGB2 STAT3 TNFRSF1B
24
Show member pathways
11.88 CD28 IL2 STAT3
25 11.86 IFNA1 IFNA2 IL2 IL2RA STAT3
26 11.84 CD7 IL2RA IL5
27 11.81 CD28 CTLA4 ITGB2
28
Show member pathways
11.77 CTLA4 IL2 IL2RA IL5
29 11.71 IFNA2 IL2 ITGAE
30 11.7 CD7 CXCR3 IL2 IL2RA IL5 ITGAE
31 11.6 CD28 CTLA4 TNFRSF8
32 11.55 CD28 CTLA4 IL2RA IL5 ITGAE ITGB2
33 11.52 CCL22 STAT3 TNFRSF1B
34
Show member pathways
11.37 IL2 IL2RA TNFRSF1B
35 11.34 CXCL9 CXCR3 ITGB2
36 11.28 CD28 CTLA4 IL2
37 11.28 CD28 IL2 IL2RA IL5 TNFRSF1B
38 11.26 CD28 IL2 IL2RA STAT3
39 11.21 CCL17 CCL22 CXCL9 IL2 IL5
40 11.02 CCL17 CCL22 CXCL9 IL2 IL5 ITGAE
41 10.76 CCL17 CCL22 CD28 IL2 IL2RA IL5

GO Terms for Mycosis Fungoides

Cellular components related to Mycosis Fungoides according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 CCL17 CCL22 CXCL9 DPP4 IFNA1 IFNA2
2 cell surface GO:0009986 9.65 CD28 CXCR3 DPP4 IL2RA ITGB2
3 external side of plasma membrane GO:0009897 9.17 CD28 CTLA4 CXCL9 CXCR3 IL2RA ITGAE
4 protein complex involved in cell adhesion GO:0098636 8.96 CD28 CTLA4

Biological processes related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.88 CD7 CTLA4 IFNA1 IL2
2 cell surface receptor signaling pathway GO:0007166 9.8 CD28 CXCR3 IFNA2 IL2RA TNFRSF1B
3 cell-cell signaling GO:0007267 9.8 CCL17 CCL22 CXCL9 IFNA2 IL2 ITGB2
4 regulation of receptor activity GO:0010469 9.8 CCL17 CCL22 CXCL9 IFNA1 IFNA2 IL2
5 negative regulation of inflammatory response GO:0050728 9.79 IL2 IL2RA TNFRSF1B
6 chemotaxis GO:0006935 9.78 CCL17 CCL22 CXCL9 CXCR3
7 T cell costimulation GO:0031295 9.77 CD28 CTLA4 DPP4
8 apoptotic signaling pathway GO:0097190 9.77 CD28 TNFRSF1B TNFRSF8
9 cytokine-mediated signaling pathway GO:0019221 9.76 IFNA1 IFNA2 IL5 STAT3
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.74 IFNA2 IL2 STAT3
11 neutrophil chemotaxis GO:0030593 9.73 CCL17 CCL22 ITGB2
12 positive regulation of T cell proliferation GO:0042102 9.72 CD28 IL2 IL2RA
13 humoral immune response GO:0006959 9.7 CD28 IFNA1 IFNA2
14 immune response GO:0006955 9.7 CCL17 CCL22 CD28 CD7 CTLA4 CXCL9
15 T cell activation GO:0042110 9.67 CD28 CD7 DPP4
16 chemokine-mediated signaling pathway GO:0070098 9.67 CCL17 CCL22 CXCL9 CXCR3
17 negative regulation of immune response GO:0050777 9.62 CTLA4 IL2RA
18 positive regulation of immunoglobulin secretion GO:0051024 9.61 IL2 IL5
19 T cell chemotaxis GO:0010818 9.61 CXCL9 CXCR3
20 positive regulation of isotype switching to IgG isotypes GO:0048304 9.58 CD28 IL2
21 negative regulation of lymphocyte proliferation GO:0050672 9.51 IL2 IL2RA
22 regulation of regulatory T cell differentiation GO:0045589 9.46 CD28 CTLA4 IL2 IL2RA
23 regulation of T cell homeostatic proliferation GO:0046013 9.43 IL2 IL2RA
24 inflammatory response GO:0006954 9.36 CCL17 CCL22 CXCL9 CXCR3 IFNA2 IL2RA
25 apoptotic process GO:0006915 10.01 CXCR3 IFNA2 IL2RA ITGB2 TIA1 TNFRSF1B

Molecular functions related to Mycosis Fungoides according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CCL17 CCL22 CXCL9 IFNA1 IFNA2 IL2
2 type I interferon receptor binding GO:0005132 9.16 IFNA1 IFNA2
3 chemokine activity GO:0008009 9.13 CCL17 CCL22 CXCL9

Sources for Mycosis Fungoides

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....